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Kallikrein-kinin and renin-angiotensin systems in rat renal lymph. Rat
renal lymph contains 254 17 nglml (x SEM, N = 20) of immunoreac-
tive glandular kallikrein. Like the immunoreactive glandular kallikrein
in plasma, it is biologically inactive. Gel filtration of renal lymph reveals
profiles for immunoreactive glandular kallikrein, protein, and inhibition
of trypsin and kallikrein which resemble those seen for plasma except
that high molecular weight plasma components are reduced or missing
in renal lymph. In contrast, gel filtration of thoracic lymph reveals
immunoreactive glandular kallikrein and protein profiles which are
indistinguishable from those seen with plasma. Renin levels are 170-fold
higher in renal lymph than in thoracic lymph while angiotensin-
converting enzyme levels are only 16% those of thoracic lymph. In
keeping with the high renin and low converting enzyme activities, renal
lymph contains high levels of angiotensin I. Immunoreactive glandular
kallikrein levels in renal lymph, thoracic lymph and plasma do not show
the striking differences observed for renin.
Les systemes kallikréine-kinine et renine-angiotensine dans Ia lymphe
rénale de rat. La lymphe rénale de rat contient 254 17 ng/ml (x SEM, N
= 20) de kallikréine glandulaire immunoréactive. Comme Ia kallikréine
glandulaire immunoréactive plasmatique, elle est biologiquement inac-
tive. La filtration sur gel de lymphe rénale révèle des profils de
kallikréine glandulaire immunoréactive, de protéines, d'inhibiteurs de
Ia trypsine et de kallikréine qui ressemblent a ceux vus pour Ic plasma, a
l'exception que des constituants plasmatiques de haut poids molécu-
laire sont diminués ou absents dans Ia lymphe rénale. A l'opposé, Ia
filtration sur gel de lymphe thoracique révéle des profils de kallikréine
glandulaire immunoréactive et de protéines qui ne sont pas distingua-
bles de ceux du plasma. Les niveaux de refine sont 170 fois plus élevés
dans Ia lymphe rénale que dans Ia lymphe thoracique, tandis que les
niveaux d'enzyme de conversion de l'angiotensine sont seulement 16%
de ceux de Ia lymphe thoracique. En mCme temps qu'une rCnine ClevCe
et que de faibles activités d'enzyme de conversion, Ia lymphe rénale
contient des niveaux élevés d'angiotensine I. Les niveaux de kallikréine
glandulaire immunoréactive dans Ia lymphe rénale, Ia lymphe thoraci-
que et Ic plasma ne montrent pas les differences frappantes observées
pour Ia rénine.
It has been suggested that the renin-angiotensin and kalli-
krein-kinin systems act as opposing forces in the regulation of
blood pressure (BP) [1]. Renin is released into the circulation by
the kidney and exists in very high levels in renal lymph [2].
Because the kidney is a rich source of kallikrein, the question
arises as to whether or not the kidney could also secrete
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kallikrein into the bloodstream, particularly since Roblero et al
[31 detected kallikrein in the perfusate as well as in the urine of
the isolated perfused rat kidney.
Immunoreactive glandular kallikrein does indeed exist in rat
plasma, as first reported by Nustad, Orstavik, and Gautvik [4].
Studies in our laboratory suggest a role for the kidney in the
clearance and/or metabolism of immunoreactive glandular kalli-
krein from plasma [5], but this does not preclude the possibility
that the kidney may also secrete kallikrein into the circulation.
Since kallikrein is localized in the tubular cells of the distal
nephron [6], the major route by which the enzyme could enter
the bloodstream would appear to be via the interstitium and the
lymph. To study this possibility, we looked at the components
of the kallikrein-kinin system in rat renal lymph, using compo-
nents of the renin-angiotensin system for comparison. As a
control, we also examined lymph obtained from the thoracic
duct of rats in which contribution from the kidneys was
eliminated by tying off the renal lymphatics.
Methods
The following materials were obtained commercially: bovine
trypsin and soybean trypsin inhibitor (Worthington Corp.,
Freehold, New Jersey); Sephadex G-150 and molecular weight
marker proteins (Pharmacia, Piscataway, New Jersey); 3H-
tosyl-L-arginine methyl ester (Amersham, Arlington Heights,
Illinois); 3H-BZ-Phe-Ala-Pro (Ventrex, Portland, Maine); S-
2266 (D-Val-Leu-Arg-pNA) was obtained from Kabi Diagnos-
tica, Stockholm, Sweden; ['4C]-hemoglobin (New England Nu-
clear Corporation, Boston, Massachusetts); cathepsin D and
bovine pancreatic trypsin inhibitor (Sigma Chemical Company,
St. Louis, Missouri); angiotensin I and lysylbradykinin (Penin-
sula, Belmont, California); captopril (SQ 14225) was obtained
from Squibb, Princeton, New Jersey; mactin (Abbott, Chicago,
Illinois); Trasylol was a gift from Bayer AG, Wueppertal, West
Germany; Affi-Gel 10 (BioRad, Richmond, California). All
other chemicals were of reagent or ultrapure grade.
Collection ofrat renal lymph. Male Sprague-Dawley rats (250
to 330 g) were anesthetized with mactin (150 mg/kg body
weight) and placed on a heated, thermostatically controlled
table. Rectal temperature was monitored by a thermistor and
maintained at 37 to 38°C. A tracheotomy was performed and a
catheter was placed in the right jugular vein. A solution of 5%
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mannitol in isotonic saline was infused at a constant rate of 5
mi/hr and maintained during the collection of renal lymph. The
left kidney was exposed by a flank incision and renal hilar
lymphatics were occluded by a fine silk ligature placed on and
around the outer aspect of a lymph node situated above the left
renal artery near its origin from the aorta. The left kidney was
placed in a stabilized cup (Lucite®) and covered with mineral
oil. A major renal hilar lymphatic was cannulated with polyeth-
ylene tubing of approximately 0.25 mm outer diameter. Renal
lymph was collected in a small polyethylene tube packed in ice
for a 2- to 4-hr period and then frozen immediately.
Collection of rat thoracic duct lymph. Following an overnight
fast, rats were anesthetized with ether and the thoracic and
renal areas were approached via left flank incision. To eliminate
any contribution from renal lymph to the thoracic duct lymph,
the right and left kidneys were each tied off with a single ligature
occluding the renal artery, vein, and ureter. Lymph from the
thoracic duct was then obtained via a PE-50 tubing cannula
according to the method of Bollman, Cain, and Gridlay [71.
Following the surgical preparation, the animals were placed in a
restraining cage [8] with free access to water. Lymph was
collected in a plastic tube packed in ice for a 2- to 3-hr period
(volume - 4 ml) and immediately frozen.
Collection of rat plasma. Pooled rat plasma was collected in
heparin as described previously [5].
Kallikrein radioimmunoassay. Assays were carried out as
described by Lawton et al [5] using a new, highly purified rat
urinary kallikrein standard prepared by DE-52 ion-exchange
chromatography, Sephadex G-100 gel filtration, and affinity
chromatography using Trasylol immobilized on Affi-Gel 10.
With this new standard, assay sensitivity was improved result-
ing in a minimum detectable dose of 100 pg/tube.
Assays for angiotensins I and II. Immunoreactive angioten-
sin I and angiotensin II were determined by specific radioimmu-
noassays [9, 101 using 50 pi of tenfold diluted lymph samples.
Goat antiserum to angiotensin I (a gift of Dr. Robert J.
Workman, Gerontology Research Center, NICH, NIH, Balti-
more, Maryland) showed less than 0.5% cross-reaction with
angiotensin II while the goat antiserum to angiotensin II (also
from Dr. Workman) showed less than 1% cross-reaction with
angiotensin I. The identities of the immunoreactive angioten-
sins were confirmed by thin layer chromatography on silica gel
plates [11].
Renin assays. Renin activity was determined by the rate of
formation of angiotensin I from rat angiotensinogen during
incubation with unfractionated plasma from nephrectomized
rats. The incubation mixture consisted of 50 d of tenfold
diluted lymph, 20 1.d of plasma from nephrectomized rats, 5 d
of 125 mri diisopropyl fluorophosphate in propanol, 5pJ of 125
mM phenylmethanesulfonyl fluoride in propanol, and 420 d of
0.1 M phosphate buffer, pH 7.0, containing EDTA (10 mM) and
8-hydroxyquinoline sulfate (1.6 mM). After incubation for 3 hr
at 37°C, the reaction was stopped by chilling in ice; generated
angiotensin I was determined by radioimmunoassay [9]. Renin
activity was calculated as the difference between angiotensin I
generated at 37°C; the control value obtained after an identical
mixture was incubated for 3 hr on ice. Renin values are
expressed in nanograms of angiotensin I per hour per milliliter
of sample.
Bioassay. Kininogenase activity was determined by kinin
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Fig. 1. Comparison of logit-log plots for rat urinary kallikrein (RUK)
standard (0—0), rat renal lymph (•—•), and rat plasma (•—•).
release from highly purified human low molecular weight kinin-
ogen [121. Samples were incubated with excess substrate for 1
hr at 37°C then quick-frozen on dry ice and stored at —20°C
until assayed. Generated kinin was measured by bioassay on
the isolated rat uterus using synthetic lysylbradykinin as the
standard [13]. The presence of angiotensin-converting enzyme
(ACE) was demonstrated by generation of angiotensin II from
angiotensin I as previously described [141 and by the ability to
destroy bradykinin.
Angiotensin-converting enzyme. ACE activity was measured
in lymph (diluted 1/10 to 1/100) and plasma (diluted 1/100 to
1/500) using [3H]-Bz-Phe-Ala-Pro (Ventrex) as described by the
manufacturer. In brief, the assay relies on the hydrolysis of
substrate to yield [3H]-Bz-Phe which is partitioned into the
organic phase for counting. The specificity of measured activity
for ACE was demonstrated by inhibition with captopril or
SQ2O,88 1.
Other enzyme assays. 3H-TAME esterase activity was mea-
sured by the method of Imanari et al [15] and cathepsin-like
proteases were assayed by hydrolysis of ['4C]-hemoglobin as
described by Williams and Lin [161 (no catheptic activity was
detected in lymph samples). S-2266 assays of trypsin and
kallikrein were performed at 37°C and pH 7.4 using 0.5 mM
substrate.
Inhibitor assays. Samples were preincubated with appropri-
ate enzymes for 30 mm at 25°C and residual enzymatic activity
was determined as described above.
Kininogen in lymph. A 50-j.d sample of renal lymph contain-
ing 18 mi EDTA was incubated with 100 ng of rat urinary
kallikrein at 37°C for 1 hr. Generated kinin was assayed by
radioimmunoassay [17].
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Volume added (tl):
Incubation mixture
(1 hr at 37°C)
Al 2ag/m/ 200 200 200 200 200
Buffera 25 25
Lymph 25 25
Lymph/18 mM EDTA 25
°0.1 M Tris/0.025% NaN3/0.1% BSA, pH 7.4
Fig. 2. Conversion of angiotensin I to angiotensin II by rat renal lymph
and inhibition of the conversion by EDTA as demonstrated on the rat
uterus.
Results
Rat renal lymph contained immunoreactive glandular kalli-
krein which cross-reacted in a manner parallel to the standard
curve in a radioimmunoassay (RIA) for rat urinary kallikrein
(Fig. 1). As previously reported [5] rat plasma did not cross-
react in a parallel fashion. Lymph samples contaminated with
blood also deviated from parallelism. Measurement of 20 indi-
vidual lymph samples revealed 254 17 ng antigen/mi (x
SEM) and recovery of standard kallikrein added to lymph was 92
10% (N = 4).
Initial attempts to see if the immunoreactive kallikrein had
biological activity were complicated by the presence of kininase
activity. When 25 d of pooled lymph from seven rats (contain-
ing 400 ng kallikrein antigen/mi) were incubated with 500 ng of
kinin for 15 mm at 37°C and pH 7.4, 100 ng of kinin were
destroyed. All of this activity was due to angiotensin-converting
enzyme (kininase II) since it could be completely inhibited by
18 mM EDTA or by l0- M captopril (ID50 - 5 x l0 M). In
addition, it could be shown that renal lymph converted angio-
tensin I to angiotensin II, as measured on the isolated rat
uterus, and this conversion could be inhibited by EDTA (Fig.
2). Therefore, to abolish kininase effects, all lymph samples
were made 18 m in EDTA prior to incubation with kininogen.
After kininase inhibition, however, neither kininogenase activi-
ty nor direct oxytocic activity was detected in any of three
separate lymph pools studied, although all three pools pos-
sessed [3H]-TAME esterase activity. This esterase activity was
not inhibited by SBTI and was only weakly inhibited by a level
of Trasylol sufficient to totally inhibit an amount of rat urinary
kallikrein with equivalent esterase activity.
Attempts to use trypsin to see if the antigen represented a
proenzyme were thwarted by the high levels of trypsin inhibi-
tory activity in lymph. A comparison of the inhibition of both
trypsin and kallikrein by lymph and plasma showed that kalli-
krein inhibition was weaker than trypsin inhibition in each case
(Fig. 3). With plasma, inhibition of both enzymes reached a
plateau which was not observed with lymph.
Initial experiments in which a low level of rat urinary
kallikrein was mixed with lymph and subsequently incubated
with kininogen resulted in measurable released kinin. This was
unexpected since the levels of kallikrein used should have been
inhibited by the lymph. It was subsequently shown that the
kinin was actually released from endogenous kininogen before
inhibition occurred. In fact, examination of the lymph sample
pooled from five rats (containing 285 ng kallikrein antigen/ml)
revealed the presence of considerable amounts of kininogen
(Table 1). Kininogen was determined on the basis of kinin
released by the addition of excess kallikrein; kinin was mea-
sured by radioimmunoassay. Assay of lymph before the addi-
tion of kallikrein revealed the apparent presence of 20 ng/ml
free kinin. This finding was not verified by bioassay and can
probably be explained by the cross-reaction of kininogen (<
2%) in the radioimmunoassay. When excess kallikrein was
incubated with the lymph, a kinin concentration of 130 nglml
was detected. When human kininogen was added to lymph prior
to the incubation with kallikrein, recovery of kinin from the
added kininogen was 94%.
Upon Sephadex G-150 gel filtration of renal lymph, immuno-
reactive glandular kallikrein eluted as two peaks with apparent
molecular weights of 85,000 and 35,000 daltons (Fig. 4, [18]).
The absorbance profile suggested that relatively little high
molecular weight protein was present in renal lymph. The major
protein peak corresponded to the elution volume of alubmin
(67,000 daltons). Although some weak inhibitory activities were
observed at the void volume, trypsin and kallikrein inhibitory
activities each eluted as one major peak with apparent molecu-
lar weights of 65,000 and 80,000 daltons, respectively. The
major peak of [3H]-TAME esterase activity also occurred at an
apparent molecular weight of 80,000 daltons. No esterase
activity was observed associated with the 35,000-dalton peak of
immunoreactive kallikrein.
In comparison, gel filtration of thoracic lymph (Fig. 5)
revealed profiles for protein and immunoreactive glandular
kallikrein which were virtually identical to those seen for
plasma. Thoracic lymph, like plasma, showed nonparallel
cross-reaction in the radioimmunoassay.
An extension of the comparison between renal and thoracic
lymph is given in Table 2. Both sets of lymph values are related
to plasma values when appropriate. In all parameters studied,
thoracic lymph was very similar to plasma. Immunoreactive
glandular kallikrein levels are similar in renal lymph, thoracic
lymph, and plasma. In contrast, renal lymph contains levels of
renin which are 170-fold those of thoracic lymph. In addition,
angiotensin I is present in high levels in EDTA-treated renal
lymph but could not be detected in thoracic lymph while
angiotensin-converting enzyme activity in renal lymph is only
16% of those of thoracic lymph and plasma.
Discussion
The presence of kininogen as well as kallikrein in human
urine [19], together with the localization of kallikrein [6] and
kininogen [20] in tubular cells of the distal nephron of rat and
human kidneys, respectively, suggests that generation of kinin
:1, 44
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Sample
Kinin contenta
ng/ml
Lymph alone 20
Lymph + RUK 130
Kininogenb + RUK 197
Lymph + Kininogen + RUK 315c
Buffer + RUK 0
differential inhibition by Trasylol, and the absence of any
esterase activity in the 35,000-dalton peak of antigen seen upon
gel filtration, clearly indicate that the TAME esterase activity
Plasma + 1.7 RUK does not represent kallikrein.
The high levels of trypsin inhibitory activity in lymph pre-
vented attempts to see if the antigen represented a proenzyme.
Kallikrein inhibition by lymph, however, was considerably
weaker than that by plasma and the absence of any plateau
phase in the lymph inhibition profiles (Fig. 3) suggested that t2-
macroglobulin was not present in the lymph. These low levels
of kallikrein inhibition may well explain the parallel cross-
reaction of lymph in the RIA, since it is the kallikrein inhibitors
in plasma which probably account for deviation from
parallelism.
To try and gain some additional information about the
immunoreactive glandular kallikrein in lymph, gel filtration
studies were performed. Nustad, Orstavik, and Gautvik [4] first
reported that, upon gel filtration of rat plasma, three peaks of
immunoreactive glandular kallikrein were seen. Studies in our
laboratory [5] subsequently showed that the first two peaks,
representing enzyme-inhibitor complexes, showed nonparallel
cross-reaction in the radioimmunoassay. The third peak, which
had the same elution volume as rat urinary kallikrein, cross-
reacted in a parallel fashion but was devoid of biological
activity. This peak was found to increase dramatically following
bilateral nephrectomy but to decrease after sialoadenectomy,
suggesting that the kidney plays an important role in the
clearance and/or metabolism of glandular kallikrein from rat
plasma, while the salivary glands are a major source of antigen.
This view is supported by the finding of Rabito et al [23] who
detected a negative arteriovenous difference across the kidney
but a positive difference across the salivary glands. Upon gel
filtration of renal lymph, immunoreactive kallikrein eluted as
two peaks corresponding to the two smaller molecular weight
peaks present in plasma. Negligible high molecular weight
protein is present in renal lymph, as judged by the absorbance
profile, and very little inhibitory activity was seen at the void
volume. The absence of a2-macroglobulin had already been
suggested by the lack of plateau phase in the inhibition curves
for lymph (Fig. 3). The major peak of kallikrein inhibition in
renal lymph eluted earlier than that for trypsin inhibition which
agrees with the data obtained by Hojima, Isobe, and Moriya
[24] for rat plasma and suggests that the kallikrein inhibitor is
not cs1-antitrypsin. The overall pattern seen for renal lymph is
one in which the profiles for immunoreactive glandular kalli-
krein, protein, and trypsin and kallikrein inhibition all resemble
Lymph + 1 p.g
trypsin
B
Lymph + 1.7 g RUK
0.3
Table 1. Demonstration of kininogen in rat renal lymph based on
increased kinin content following incubation with kallikrein
E
•1
2 3 4 5 0
0.4
0.3
0.2
0.1
0.2
0.1
0
0.4
0.3
0.2
0.1
0
Volume of lymph, /2/
4 8 12 16 20
Plasma + 0.9 g
trypsin
Abbreviation: RUK, rat urinary kallikrein.
The content was determined by radioimmunoassay.
Highly purified human low molecular weight kininogen was used.
The value represents 94% recovery.
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4 6 8 10
Fig. 3. Inhibition of trypsin and kallikrein by rat renal lymph and rat
plasma. Residual enzymic activity was measured against D-Val-Leu-
Arg-pNA. A Lymph + I pg IPypsin. B Lymph + 1.7 p.g RUK. C Plasma
+ 0.9 p.g trypsin. D Plasma + 1.7 pg RUK. Note the differing scales on
the abscissas.
could occur in the lumen of the distal nephron as well as
intracellularly. The recent report that rat renal kallikrein exists
in fractions enriched in basolateral membranes [21], together
with the finding that kallikrein occurs in the perfusate as well as
in the urine of the isolated perfused rat kidney [3] suggests that
kallikrein may be secreted into the bloodstream by way of the
lymph and raises the possibility of a third site of kinin forma-
tion, namely the interstitium. To examine this possibility more
closely, we looked at components of the kallikrein-kinin system
in rat renal lymph.
Immunoreactive glandular kallikrein was detected in renal
lymph and showed parallel cross-reaction in the radioim-
munoassay. The presence of kininogen in renal lymph would
also tend to support the possible interstitial formation of kinins.
However, even after kininase inhibition, no kininogenase activ-
ity could be detected in any of three renal lymph pools studied,
despite the presence of TAME esterase activity in all three
pools. DeBono and Mills [22] reported on the presence of
TAME esterase activity in dog renal lymph and concluded that
it represented kallikrein. In our present study in the rat,
however, the lack of correlation with biological activity, the
100
Fig. 4. Sephadex G-150 ge/filtration of rat re-
na/lymph. Column, 1.6 x 91 cm; eluant,
80 0.01 M Tris-HCI/O.15 M NaCI/liter m EDTA,
pH 7.4; flow rate, 8 ml/hr; fraction volume,
c 2.65 ml. The column was standardized using60 a blue dextran, ferritin, catalase, bovine serum
albumin, ovalbumin, chymotrypsinogen, and
g ribonuclease. Sample was a pool from five
40 rats. Applied 0.4 ml lymph (4.1 A280 U) in a
final volume of 2 ml. Symbols are: (0—0)
A20; (A—A) kallikrein antigen, ng/ml; (I—I)
20 [3HJ-TAME esterase activity (cpm); (U—LI) %
trypsin inhibition; (U—U) % kallikrein
inhibition. (Published with permission from
0 [18].)
Fig. 5. Sephadex G-150 gel fl//ration of rat ihoracic lymph. Conditions
were as described for Figure 4. Applied 0.5 ml lymph (20 A280 U) was in
a final volume of 2 ml. Symbols are: (0—0) A280; (A—A) kallikrein
antigen (ng/ml).
those seen for plasma except that high molecular weight plasma
components are reduced or missing. This is consistent with the
idea of lymph representing plasma which has passed through a
molecular weight filter.
When thoracic lymph was gel-filtered, the immunoreactive
glandular kallikrein and protein profiles were indistinguishable
from those seen with plasma. Indeed, in all the parameters
studied in Table 2, thoracic lymph was very similar to plasma,
suggesting that there may be free exchange between lymph and
plasma at the level of the thoracic duct. The 170-fold difference
in renin values and thoracic lymph is striking. While we cannot
eliminate the possibility that these differences in values are
reflective of different levels of renin inhibitor (no such inhibitor
has ever been reported in either plasma or lymph), we consider
the possibility extremely unlikely.
Angiotensin I was also present in renal but not thoracic
lymph. The angiotensin II content of renal lymph, however,
was low (3 1 1 2 ng/ml; N = 10). These data are consistent
with the high levels of renin and low levels of converting
enzyme in renal lymph, although effects of angiotensinases
cannot be discounted. It is particularly interesting that angio-
tensin-converting enzyme is so low compared to thoracic lymph
and plasma, since the proximal tubules of the kidney are a rich
source of this enzyme [25].
Table 2. Comparison of components of kallikrein-kinin and renin-
angiotensin systems in rat renal lymph, thoracic lymph, and plasma
Renal lymph Thoracic lymph Plasma
A280 16.5 2 (10) 44.2 3 (7) 50.0 3 (6)
Kallikrein,
ng/ml 254 17 (20) 230 12 (7)b 180 5 (6)
Renin,
ngAi/
mi/hr 172 52 (10) 1.0 0.3 (5) ND
Al, ng/ml 191 78 (10) < 0.4 (5) ND
ACE, U 690 100 (13) 4150 230 (7) 4500 160 (3)
Abbreviations: ACE, angiotensin-converting enzyme; Al, angioten-
sin 1; ND, not determined.
Values are given as x sEM; figures in parenthesis indicate N
values.
b Values were not paralleled in RIA; data are only semi-quantitive.
The levels of immunoreactive kallikrein in renal lymph,
thoracic lymph, and plasma did not show the striking differ-
ences observed for renin. While this does not preclude the
possibility that there is some passage of kallikrein from the
tubular cells into the interstitium and the lymph, we feel that
this data together with the low levels of angiotensin-converting
enzyme (another tubular enzyme) in renal lymph and the
observed gel filtration profiles can all be explained if renal
lymph is assumed to represent primarily plasma which has
passed through a molecular weight filter (peritubular
vasculature?).
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